SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

Typhaneoside for Progressive Supranuclear Palsy

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-typhane-psp
Related Entities
clinical-trials-typhane-psp
Metadata
slugclinical-trials-typhane-psp
entity_typeclinical
kg_node_idNone
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (105)
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp60%
mentions🔬PSP and CBD both involve 4R-tau but produce distinct neuropa60%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
see_also📖Genes60%
see_also📖Aging vs Neurodegeneration: Mechanistic Comparison Matrix60%
see_also📖Frontotemporal Dementia (FTD)60%
see_also📖Apoptosis in Neurodegeneration60%
see_also📖cdkn2a60%
see_also📖DUSP10 Gene60%
see_also📖Alzheimer Indonesia60%
see_also📖Dementia Australia60%
see_also📖diseases-amyotrophic-lateral-sclerosis60%
see_also📖Packard Center for ALS Research60%
see_also📖Autophagy Enhancement Drug Screening for Neurodegeneration60%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp54%
related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa54%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%
related🧫Metabolic Pathway-Targeted Therapy in ALS54%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%
related🧫N-of-1 Clinical Trial Design for CBS/PSP54%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%
related🧫Progranulin Replacement Therapy for FTD — Vector Development54%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%
related🧫TDP-43 PET Ligand Development for FTD and ALS54%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%
mentions🧫4R-Tau Targeting Therapies for PSP and CBS50%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri50%
mentions🧫Brainstem Circuit Modulation for PSP50%
mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre50%
mentions🧫PSP and CBS Biomarker Validation Study50%
mentions🧫Tau Pathology Initiation Zone Identification50%
mentions🧫Tau Spreading Network Mapping via Spatial Transcriptomics in50%
mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%
mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%
mentions🧪Competitive APOE4 Domain Stabilization Peptides50%
mentions🧪APOE Isoform Expression Across Glial Subtypes50%
related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub